The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

BACKGROUND: Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inhibitors and immunomodulatory drugs. Despite these options, almost all patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Striha, Alina, Ashcroft, A. John, Hockaday, Anna, Cairns, David A., Boardman, Karen, Jacques, Gwen, Williams, Cathy, Snowden, John A., Garg, Mamta, Cavenagh, Jamie, Yong, Kwee, Drayson, Mark T., Owen, Roger, Cook, Mark, Cook, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842589/
https://www.ncbi.nlm.nih.gov/pubmed/29514706
http://dx.doi.org/10.1186/s13063-018-2524-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842589/
https://www.ncbi.nlm.nih.gov/pubmed/29514706
http://dx.doi.org/10.1186/s13063-018-2524-8

Ejemplares similares